Position in ALNY
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$303,137
-$30,049 QoQ
Shares Held
1,007
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#538
of 780 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Breakwater Capital Group holds $2,533,174 across 7 Biotechnology names. ALNY ranks #4 (12.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,992 | $989,486 | |
| 2 | DNLI |
Denali Therapeutics Inc.
|
15,601 | $401,257 | |
| 3 | CYTK |
Cytokinetics Inc
|
3,941 | $335,733 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
1,007 | $303,137 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
2,832 | $246,242 | |
| 6 | REPL |
Replimune Group, Inc.
|
19,900 | $220,293 | |
| 7 | RXRX |
Recursion Pharmaceuticals, Inc.
|
10,089 | $37,026 |
All Filings in ALNY
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $303,137 | 1,007 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $333,186 | 1,007 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $400,433 | 1,007 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $468,312 | 1,027 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $334,894 | 1,027 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $277,850 | 1,029 | Shares | Sole | 2025-04-10 | |
| 2024-12-31 | $242,133 | 1,029 | Shares | Sole | 2025-01-14 | |
| 2024-09-30 | $283,280 | 1,030 | Shares | Sole | 2024-10-04 | |
| 2024-06-30 | $249,075 | 1,025 | Shares | Sole | 2024-07-26 | |
| No filing history on record for this holder in this stock. | ||||||